Evidence map›Paper›PMID 32781747›Full record

ArticleMolecules (Basel, Switzerland)2020

Water-Extracted

An-Yi Cheng, Yi-Chung Chien, Han-Chung Lee, Yi-Hsien Hsieh, Yung-Luen Yu

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Potential Active Compounds ofFood science & nutrition · 2025
    Review
  3. Article
  4. Article
  5. A Phyto-mycotherapeutic Supplement, NamelyInternational journal of molecular sciences · 2024
    Article
  6. Article
  7. The medicinal mushroomFrontiers in pharmacology · 2023
    Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

An-Yi ChengThe Ph.D. Program of Biotechnology and Biomedical Industry, China Medical University, Taichung 40402, Taiwan.
Yi-Chung ChienGraduate Institute of Biomedical Sciences, China Medical University, Taichung 40402, Taiwan.
Han-Chung LeeSchool of Medicine, College of Medicine, China Medical University, Taichung 40402, Taiwan.
Yi-Hsien HsiehDepartment of Biochemistry, School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.ORCID 0000-0003-4942-1888
Yung-Luen YuThe Ph.D. Program of Biotechnology and Biomedical Industry, China Medical University, Taichung 40402, Taiwan.ORCID 0000-0002-9745-1726
China Medical University · TWAsia University · TWChung Shan Medical University Hospital · TW

Funding

China Medical University, Taiwan CMU105-TC-01; CMU108-MF-01; DMR-108-BC-4; DMR-108-BC-10; DMR-109-133Ministry of Science and Technology, Taiwan MOST106-2320-B-039-051-MY3; MOST107-2320-B-039-004
6 · The paper itself

Abstract

Glioblastoma is one of the most common and most aggressive brain cancers. The current treatment is mainly surgery, chemotherapy, and radiation therapy, but the results are not satisfactory.

Indexed as

Antineoplastic AgentsApoptosisCell Line, TumorCell MovementCell ProliferationCyclin-Dependent Kinase 2CyclinsEpithelial-Mesenchymal TransitionGlioblastomaHumansReishiS Phase Cell Cycle CheckpointsWaterAntineoplastic AgentsCyclin-Dependent Kinase 2CyclinsWaterapoptosisCDK2Ganoderma lucidumglioblastomaS phase arrest

Identifiers

PMID32781747
PMCPMC7464863
OpenAlexW3047314015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.